SCN9A and erythromelalgia: While the precise mechanism of AZ106 remains unconfirmed, personal communication with AstraZeneca suggests it acts as a non‐specific Nav channel inhibitor, targeting proteins synthesised by SCN1‐10A and SCN1‐10B, including SCN9A which encodes the NaV 1.7 channel, implicated in erythromelalgia.